key: cord-0708250-qk028tcd authors: Patel, Raj H.; Acharya, Arpan; Mohan, Mahesh; Byrareddy, Siddappa N. title: COVID‐19 and AIDS: outcomes from the co‐existence of two global pandemics and the importance of chronic antiretroviral therapy date: 2020-08-11 journal: J Med Virol DOI: 10.1002/jmv.26416 sha: a55d5a0bd4065051a6143ac07234cd08753364aa doc_id: 708250 cord_uid: qk028tcd The outbreak of coronavirus disease 2019 (COVID‐19), caused by severe acute respiratory syndrome 2 (SARS‐CoV‐2), has created a worldwide pandemic, raising multitude of challenges and uncertainties regarding disease management specific to immunocompromised patient populations. Despite over ~16 million confirmed cases of COVID‐19 worldwide as of July 25, 2020, there is a dearth of reports describing the co‐infection of Human Immunodeficiency Virus (HIV) and SARS‐CoV‐2. There are various unknowns regarding the simultaneous impact from these two diseases, despite the fact that the majority of patients with acquired immunodeficiency syndrome (AIDS) are immunocompromised and have comorbidities which can predispose them to severe clinical symptoms, and poorer prognosis, from COVID‐19. A large majority of reports indicate that HIV patients with normal CD4 T‐cell counts and suppressed viral loads and receiving regular, chronic antiretroviral therapy (cART) do not present with a severe clinical course of COVID‐19 and may not be at an increased risk of developing SARS‐CoV‐2 infection. These favorable indications for HIV patients may be the byproduct of a potential protective factor conferred by antiretroviral therapy which has also been used successfully in previous coronavirus epidemics. This article is protected by copyright. All rights reserved. The outbreak of coronavirus disease 2019 , caused by severe acute respiratory syndrome 2 (SARS-CoV-2), has created a worldwide pandemic, raising multitude of challenges and uncertainties regarding disease management specific to immunocompromised patient populations [1] . Despite over ~16 million confirmed cases of COVID-19 worldwide as of July 25, 2020, there is a dearth of reports describing the co-infection of Human Immunodeficiency Virus (HIV) and SARS-CoV-2 [2] . There are various unknowns regarding the simultaneous impact from these two diseases, despite the This article is protected by copyright. All rights reserved. fact that the majority of patients with acquired immunodeficiency syndrome (AIDS) are immunocompromised and have comorbidities which can predispose them to severe clinical symptoms, and poorer prognosis, from COVID-19 [3, 4] . A large majority of reports indicate that HIV patients with normal CD4 T-cell counts and suppressed viral loads and receiving regular, chronic antiretroviral therapy (cART) do not present with a severe clinical course of COVID-19 and may not be at an increased risk of developing SARS-CoV-2 infection [5] [6] [7] [8] [9] . These favorable indications for HIV patients may be the byproduct of a potential protective factor conferred by antiretroviral therapy which has also been used successfully in previous coronavirus epidemics [10, 11] . SARS-CoV-2 and HIV carry numerous similarities as they are both ribonucleic acid (RNA) viruses capable of undergoing mutations and recombination under selection pressure within the host [12] . During the previous SARS-CoV epidemic, the HIV-1 protease inhibitor nelfinavir was found to strongly inhibit the cytopathic effect induced by SARS-CoV infection [10] . Lopinavir was also found to show efficacy both in vivo and in vitro, reducing viral titers and shortening disease progression in case of MERS-CoV infected animals [11] . HIV-1 protease inhibitors including lopinavir/ritonavir and darunavir have been found as efficacious treatment options in patients co-infected with COVID-19 and HIV by reducing SARS-CoV-2 viral loads and accelerating recovery [13] [14] [15] . However, recently, remdesivir, a broad-spectrum antiviral drug, has also shown promising results in suppressing SARS-CoV-2 replication in a double-blind, randomized, placebo-controlled trial, where adults hospitalized with COVID-19 that received remdesivir showed reduced respiratory tract involvement [16] . Similarly, tenofovir has also been found to be highly efficacious against SARS-CoV-2 through potently inhibiting SARS-CoV-2 RNA dependent RNA polymerase [17] . However, it is important to recognize that clinical evidence regarding the role of antiretroviral therapy, specifically, lopinavir/ritonavir is still emerging. The current COVID-19 treatment guidelines issued by the NIH recommend against the use of lopinavir/ritonavir protease inhibitors (AIII) for the treatment of COVID-19, and is restricted to clinical trials [18, 19] . [16] . Notably, previous administration of antiretroviral This article is protected by copyright. All rights reserved. therapy, CD4 T-cell counts, CD4/CD8 ratio, and pre-existing comorbidities were not significantly different in recovered patients vs. still-admitted individuals in this study [20] . The authors in this study concluded that HIV-infected individuals should not be Out of the 236 patients, 15 were admitted to the ICU, 20 died, and 151 were hospitalized with mild-moderate symptoms [22] . The study notes that HIV-positive patients who received tenofovir/emtricitabine (TDF/FTC) as part of cART regimen were found to have a lower risk for COVID-19 and related hospitalization than those receiving other therapies. This finding conforms with various other molecular docking and case series studies, which demonstrate more favorable outcomes for HIV/COVID-19 patients on tenofovir-based regimens [11, 15] . However, this study does not include non-AIDS comorbidities, such as CD4+ T-cell counts, HIV viral RNA loads, and other key confounders, which may influence the results. Further, this study did not report whether or not the patients receiving TDF/FTC had fewer comorbidities than those receiving other forms of ART. Given the limited available evidence and mixed results from various studies as noted above, it is difficult to draw effective conclusions regarding the outcomes for HIV patients when infected with SARS-CoV-2 at this time and therefore more data/studies are needed to make meaningful conclusions. It is also important to recognize that these studies contain limited sample sizes, geographical limitations, and inconsistencies in information, which creates a challenge in stratifying the data to understand the impact of antiretroviral therapy in addition to taking into account individual patient factors and comorbid conditions. Thus, in order to further elucidate the role of cART on SARS-CoV- HIV/SARS-CoV-2 co-infections in all previously reported studies. Therefore, further large systematic studies are warranted in order to further determine the contribution of these specific genetic/host factors influence the clinical outcomes. Another possible factor to consider as an explanation for the low incidence of severe outcomes is the impact of social and psychological factors [23] . Are HIV patients following stricter social distancing measures and self-quarantining due to a greater perceived risk of contracting severe SARS-CoV-2 infection? It is also important to consider the backgrounds and demographics of the population represented by HIV patients, which includes drug users, poor patients living in crowded urban slums, migrant workers, sex workers, and prisoners, who may live in environments in which it may be difficult to practice successful social distancing and contact isolation. The challenges of universal HIV testing and now with COVID-19 testing also remains unsolved which can impact the reported incidence and prevalence. Although more studies are needed, it is undeniable that the overwhelming majority of available evidence regarding HIV/COVID-19 co-infected patients overwhelmingly demonstrates the positive effects of chronic antiretroviral therapy. Individuals who are unaware of their HIV diagnosis and do not have access to antiretroviral therapy may be at heightened risk of experiencing increased morbidity and mortality if infected with SARS-CoV-2. Given the benefits of chronic antiretroviral therapy in reported patients thus far, it becomes increasingly important to sustain the HIV care continuum. Healthcare centers and HIV clinics should work to continue regular follow-up visits for patients and ensure that antiretroviral therapy is adequately rationed for HIV patients and distributed in a timely manner to protect this vulnerable population. Coronavirus disease 2019 (COVID-19): A literature review HIV and SARS-CoV-2: Intersecting Epidemics with Many Unknowns Potential impact of COVID-19 in people living with HIV: experience from previous 21st century coronaviruses epidemics Epidemiology and clinical features of COVID-19: A review of current literature COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients Clinical characteristics and outcomes in people living with HIV hospitalized for COVID-19 4 Cases: HIV and SARS-CoV-2 Co-infection in patients from Long Island Recovery from COVID-19 in two patients with coexisted HIV infection Clinical features and outcomes of HIV patients with coronavirus disease HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus Treatment With Lopinavir/Ritonavir or Interferon-beta1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset How the SARS vaccine effort can learn from HIV-speeding towards the future, learning from the past COVID-19 in patients with HIV: clinical case series Computed Tomography Imaging of an HIVinfected Patient with Coronavirus Disease 2019 (COVID-19) A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19 Compassionate Use of Remdesivir for Patients with Severe Covid-19 Ribavirin, remdesivir, sofosbuvir, galidesivir, and tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study COVID-19) Treatment Guidelines. National Institutes of Health co-infection: A retrospective, record based, case series from South India Description of COVID-19 in HIVinfected individuals: a single-centre, prospective cohort Clinical features and outcome of HIV/SARS-CoV-2 coinfected patients in The Bronx Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy: A Cohort Study Impact of Social Determinants of Health on the Emerging COVID-19 Pandemic in the United States